Status:
COMPLETED
Peak Plasma Levels of Bupivacaine After an Erector Spinae Block (ESP)
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Pharmacokinetics
Anesthesia, Local
Eligibility:
All Genders
18-90 years
Brief Summary
The primary objective of the study is to measure plasma levels of bupivacaine following erector spinae (ESP) regional block in patients undergoing mastectomy.
Detailed Description
Breast cancer is one of the most frequent types of cancer in women. Mastectomy is important in treating these cases; however, sometimes it is associated with acute and chronic pain. Multimodal analges...
Eligibility Criteria
Inclusion
- ASA I-III
- Undergoing unilateral mastectomy under erector spinae block and general anesthesia
Exclusion
- Patient's refusal or inability to consent
- Allergy, hypersensibility or resistance to local anesthetic
- Contra-indication to regional anesthesia: infection in the designated area, acquired or congenital coagulopathy
- Severe hepatic or renal insufficiency (GFR\<30 mL/min)
Key Trial Info
Start Date :
June 14 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 16 2019
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT03841409
Start Date
June 14 2019
End Date
October 16 2019
Last Update
May 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2X 3E4